A fully human anti-vascular endothelilal growth factor receptor 2 (VEGFR2) IGG1 monoclonal antibody (MAB) therapy in patients with advanced cancer

被引：0
|
作者：
Youssoufian, H. [1 ]
Rowinsky, E. K. [1 ]
Fox, F. [1 ]
Hicklin, D. [1 ]
机构：
[1] ImClone Syst Inc, Branchburg, NJ USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2006年 / 21卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5
引用
收藏
页码：383 / 383
页数：1
相关论文
共 50 条
  • [1] A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer.
    Camidge, D. R.
    Eckhardt, S. G.
    Diab, S.
    Gore, L.
    Chow, L.
    O'Bryant, C.
    Temmer, E.
    Ervin-Haynes, A.
    Katz, T.
    Fox, F.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 128S - 128S
  • [2] A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumors
    Spratlin, Jennifer L.
    Eckhardt, S. Gail
    Gore, Lia
    Camidge, D. Ross
    Leong, Stephen
    O'Bryant, Cindy
    Diab, Sami
    Chow, Laura Q. M.
    Youssoufian, Hagop
    Fox, Floyd
    Cohen, Roger B.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3346S - 3346S
  • [3] Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis
    Kim, Dong Geon
    Jin, Younggeon
    Jin, Juyoun
    Yang, Heekyoung
    Joo, Kyeung Min
    Lee, Weon Sup
    Shim, Sang Ryeol
    Kim, Sung-Woo
    Yoo, Jinsang
    Lee, Sang Hoon
    Yoo, Jin-San
    Nam, Do-Hyun
    MABS, 2015, 7 (06) : 1195 - 1204
  • [4] Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2
    Wei Xie
    Daojuan Li
    Juan Zhang
    Zhike Li
    Desmond Omane Acheampong
    Yuan He
    Youfu Wang
    Zhiguo Chen
    Min Wang
    Cancer Immunology, Immunotherapy, 2014, 63 : 877 - 888
  • [5] IMC-18F1, a human IgG1 monoclonal antibody that specifically targets Vascular Growth Factor Receptor-1 (VEGFR-1)
    Schwartz, J. D.
    Rowinsky, E. K.
    Youssoufian, H.
    Zhu, Z.
    Tonra, J.
    Pytowski, B.
    Wu, Y.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 526 - 526
  • [6] Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2
    Xie, Wei
    Li, Daojuan
    Zhang, Juan
    Li, Zhike
    Acheampong, Desmond Omane
    He, Yuan
    Wang, Youfu
    Chen, Zhiguo
    Wang, Min
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (09) : 877 - 888
  • [7] Tanibirumab (TTAC-0001): A Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2)
    Lee, Sang Hoon
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (08) : 1223 - 1226
  • [8] Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)
    Sang Hoon Lee
    Archives of Pharmacal Research, 2011, 34 : 1223 - 1226
  • [9] Phase 1 clinical trial of ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) for patients with advanced cancer
    Figlin, R
    Belldegrun, A
    Crawford, J
    Lohner, M
    Roskos, L
    Yang, XD
    Foon, KA
    Schwab, G
    Weiner, L
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 87 - 87
  • [10] Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors
    Li, Jin
    Cao, Junning
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Gao, Ling
    CANCER RESEARCH, 2016, 76
12345